Desloratadine: A new, nonsedating, oral antihistamine

Slides:

Advertisements

Similar presentations

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Advertisements

W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc

Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome Paul Steinberg, MDa, Bruce E.

Efficacy and safety profile of fexofenadine HCL

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Ulrich Wahn, MDa. ‡, Eli O. Meltzer, MDb. ‡, Albert F. Finn, MDc

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis William R. Lumry, MD Journal of.

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Asthma and increased bronchial responsiveness in elite athletes: Atopy and sport event as risk factors Ilkka J. Helenius, MDa, Heikki O. Tikkanen, MDb,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Is 9 more than 2 also in allergic airway inflammation?

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

Badrul A. Chowdhury, MD, PhD

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

Efficacy and safety profile of fexofenadine HCL

Noninjection routes for immunotherapy

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis

Clinical pharmacology of H1-antihistamines in the skin

The impact of allergic rhinitis on bronchial asthma

Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol Henry Milgrom, MDa, David P. Skoner,

Conjunctivitis medicamentosa

Lawrence F. Eichenfield, MD, Lisa Beck, MD

Inhaled corticosteroids: Impact on asthma morbidity and mortality

Michael Mellon, MD Journal of Allergy and Clinical Immunology

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma Gail.

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model John M.

A review of the current guidelines for allergic rhinitis and asthma

Physician-targeted program on inhaled therapy for childhood asthma

Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: Effects of single allergen challenge Adriaan.

News & Notes Journal of Allergy and Clinical Immunology

Quality of life in adults and children with allergic rhinitis

James P. Kemp, MDa, David A. Cook, MDb, Gary A

Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization Qutayba Hamid, MD, PhD, Editor Journal.

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.

Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study Jacques de Blic, MDa, Christophe Delacourt, MDa, Muriel.

Eosinophilia and gastrointestinal symptoms after ingestion of shiitake mushrooms Aaron M. Levy, MDa, Hirohito Kita, MDb, Sidney F. Phillips, MDa, Paul.

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Peter S. Creticos, MD Journal of Allergy and Clinical Immunology

Clinical need for a nebulized corticosteroid

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections Barbara Knorr, MDa, Sherry Holland, PhDb, J.Douglas.

Vascular endothelial growth factor in patients with acute asthma

News & Notes Journal of Allergy and Clinical Immunology

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic.

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: Comparison with the allergen-induced.

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

The effects of antihistamines on cognition and performance

The 30th anniversary of the American Board of Allergy and Immunology: Then and now Lynn Des Prez a, Charles E. Reed, MD, Lawrence B. Schwartz, MDb, John.

Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled.

Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation Anthony P. Sampson, PhDa, Emilio Pizzichini, MD, PhDb,

The role and remediation of animal allergens in allergic diseases

Exercise-induced asthma: Is it the right diagnosis in elite athletes?

Preparing patients and health professionals for the transition to chlorofluorocarbon-free inhalers: The British perspective Helen Donohoe, MSc (Econ)

Inhaled β2 -agonists and airway responses to allergen

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Robert P. Schleimer, PhD Journal of Allergy and Clinical Immunology

Larry C. Borish, MDa, Harold S

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal.

The correlation between allergic rhinitis and sleep disturbance

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial Eli O. Meltzer, MDa,

News & Notes Journal of Allergy and Clinical Immunology

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Clinical relevance of inhaled corticosteroids and HPA axis suppression

Presentation transcript:

Desloratadine: A new, nonsedating, oral antihistamine Raif S. Geha, MDa, Eli O. Meltzer, MDb Journal of Allergy and Clinical Immunology Volume 107, Issue 4, Pages 751-762 (April 2001) DOI: 10.1067/mai.2001.114239 Copyright © 2001 Mosby, Inc. Terms and Conditions

Fig. 1 Space-filling model of the structures of loratadine and desloratadine. Journal of Allergy and Clinical Immunology 2001 107, 751-762DOI: (10.1067/mai.2001.114239) Copyright © 2001 Mosby, Inc. Terms and Conditions

Fig. 2 Diagram of the major pathways of allergic inflammation and potential sites for therapeutic intervention (blocked arrows) by an agent with both antiallergic and anti-inflammatory properties. Journal of Allergy and Clinical Immunology 2001 107, 751-762DOI: (10.1067/mai.2001.114239) Copyright © 2001 Mosby, Inc. Terms and Conditions

Fig. 3 Mean plasma desloratadine and 3-OH desloratadine concentrations on day 10 after oral administration of 7.5 mg of desloratadine with erythromycin or with placebo. (Adapted with permission from Banfield C et al. Clin Pharmacokinet. In press.) Journal of Allergy and Clinical Immunology 2001 107, 751-762DOI: (10.1067/mai.2001.114239) Copyright © 2001 Mosby, Inc. Terms and Conditions

Fig. 4 Mean concentration-time profiles for desloratadine (top) and 3-OH desloratadine (bottom) in 3 age groups after daily oral administration of 5 mg of desloratadine for 10 days. (Adapted with permission from Affrime M et al. Clin Pharmacokinet. In press.) Journal of Allergy and Clinical Immunology 2001 107, 751-762DOI: (10.1067/mai.2001.114239) Copyright © 2001 Mosby, Inc. Terms and Conditions

Fig. 5 Time course for reduction in SAR total symptom scores (average reflective 12-hour morning/evening TSS) for 5 mg of desloratadine and placebo. Mean baseline scores for the desloratadine and placebo groups were 14.2 and 13.7, respectively. (Adapted with permission from Meltzer EO, et al. Clin Drug Invest 2001;21:25-32.) Journal of Allergy and Clinical Immunology 2001 107, 751-762DOI: (10.1067/mai.2001.114239) Copyright © 2001 Mosby, Inc. Terms and Conditions

Fig. 6 Change from baseline in total asthma symptom scores for 5 mg of desloratadine and placebo during weeks 1 to 2 and weeks 1 to 4. Journal of Allergy and Clinical Immunology 2001 107, 751-762DOI: (10.1067/mai.2001.114239) Copyright © 2001 Mosby, Inc. Terms and Conditions

Fig. 7 Change from baseline in use of inhaled β2-agonists for 5 mg of desloratadine and placebo during weeks 1 to 2 and weeks 1 to 4. Journal of Allergy and Clinical Immunology 2001 107, 751-762DOI: (10.1067/mai.2001.114239) Copyright © 2001 Mosby, Inc. Terms and Conditions

Fig. 8 Change from baseline morning/evening reflective pruritus score in patients with CIU. Least-square mean baseline scores for desloratadine and placebo groups were 2.24 and 2.22, respectively. (Adapted with permission from Ring J. Int J Dermatol 2001;40:1-5.) Journal of Allergy and Clinical Immunology 2001 107, 751-762DOI: (10.1067/mai.2001.114239) Copyright © 2001 Mosby, Inc. Terms and Conditions